Character features of diagnosis and treatment of lung carcinoma

1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2001 г. М.; 2003.

2. Чиссов В.И., Старинский В.В, Петрова Г.В. Злокачественные новообразования в России в 2006 г. М.; 2008.

3. Ременник Л.В., Старинский В.В. Эпидемиология злокачественных новообразований. В кн.: Чиссов В.И., Дарьялова С.Л. (ред.). Избранные лекции по клинической онкологии. М.; 2000. 24–52.

4. Pira E., Pelucchi C., Buffoni L., Palmas A. et al. Cancer mortality in a cohort of asbestos textile workers. Cancer, 2005, 14; 92 (3): 580–586.

5. Grosche B., Kreuzer M., Kreisheimer M. et al. Lung cancer risk among German male uranium miners: a cohort study, 1946–1998. Br. J. Cancer. 2006; 95 (9): 1280–1287.

6. Subramanian J., Govindan R. Lung cancer in never smokers: a review. Clin. Oncol. 2007; 25 (5): 561–570.

7. Toh C.K., Gao F., Lim W.T. et al. Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. Lung Cancer. 2007; 56(2): 161–166.

8. Wakelee H.A., Chang E.T. Gomez S.L. et al. Lung cancer incidence in never smokers. Clin. Onсol. 2007; 25 (5): 472–478.

9. Трахтенберг А.Х., Чиссов В.И. Клиническая онкопульмонология. М.: ГЭОТАР Медицина; 2000.

10. Cassidi A., Duffy S.W., Myles J.P. et al. Lung cancer risk prediction: a tool for early detection. Int. J. Cancer. 2007; 120 (1): 1–6.

11. UICC. TNM classification of malignant tumours. 5th and 6th eds. Geneva: UICC; 1997 and 2002.

12. Marcus P., Bergstralh E., Fagerstrom R. et al. Lung cancer mortality in Mayo Lung Project: Impact of extended follow up. J. Natl. Cancer. Inst. 2000; 92: 1308–1316.

13. Bach P., Kelly M., Tate R. et al. Screening for lung cancer: A review of the literature. Chest 2003; 123 (1, suppl.): 72S–82S.

14. Sone S., Li F., Yang Z. et al. Characteristics of small lung concerns invisible on conventional chest radiography and detected by population based screening using spiral CT. Br. J. Radiol. 2000; 73: 137–145.

15. Henschke C.I., Yankelevitz D.F., Libby D.M. et al. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 2006; 355 (17): 1763–1771.

16. Полоцкий Б.Е., Тер1Ованесов М.Д. Рак легкого – некоторые аспекты клиники, диагностики и лечения. Рус. мед. журн. 2005; 13 (23): 1520–1531.

17. Grippi M.A. Clinical aspects of lung cancer. Semin. Roentgenol. 1990; 25: 12–24.

18. Maddison P., Newsom1Davis J., Mills K.R. et al. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell carcinoma. Lancet 1999; 353: 117–118.

19. Croteau D., Owainati A., Dalmau J. et al. Response to cancer therapy in a patient with a paraneoplastic choreiform disorder. Neurology 2001; 57: 719–722.

20. Ищенко Б.И., Бисенков Л.Н., Тюрин И.Е. Лучевая диагностика для торакальных хирургов. С-Пб.; 2001.

21. Silvestri G.A., Tanoue L.T., Margolis M.L. et al. The noninvasive staging of non-small-cell lung cancer: The guidelines. Chest 2003; 123 (1, suppl.): 147S–156S.

22. Седых С.А., Кашутина Е.И., Рубцова Н.А. Перспективы применения компьютерной томографии в ранней диагностике центрального рака легкого. Рос. онкол. журн. 2007; 1: 4–9.

23. Адасько Е.В. Роль компьютерной томографии в дифференциальной диагностике одиночных шаровидных образований легких. Автореф. дис. … канд. мед. наук. М.; 2003.

24. Седых С.А., Щетинин В.В., Адасько Е.В., Викулова Ю.В. Значение денситометрии в первичной и уточняющей КТ диагностике опухолей легких и пищевода. В кн.: Онкология на рубеже ХХI века. М.; 1999. 331–332.

25. Fritscher-Ravens A., Bohuslavizki K.H., Brandt L. et al. Mediastinal lymph node involvement in potentially resectable lung cancer: comparison of CT, positron emission tomography, and endoscopic ultrasonography with and without fine-needle aspiration. Chest 2003; 123 (2): 442–451.

26. Sioris T., Järvenpää R., Kuukasjärvi P. et al. Comparison of computed tomography and systematic lymph node dissection in determining TNM and stage in non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 2003; 23: 403–408.

27. Bradley J., Thorstad W.L., Mutic S. et al. Impact of FDGPET on radiation therapy volume delineation in non-smallcell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004; 59: 78–86.

28. Reed C.E., Harpole D.H., Posther K.E. et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 2003; 126: 1943–1951.

29. Gupta N.C., Rogers J.S., Graeber G.M. et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 2002; 122: 1918–1924.

30. Vansteenkiste J., Fischer B.M., Dooms C., Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004; 5: 531–540.

31. Gould M.K., Kuschner W.G., Rydzak C.E. et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with nonsmall-cell lung cancer: a meta-analysis. Ann. Intern. Med. 2003; 139: 879–892.

32. Lardinois D., Weder W., Hany T.F. et al. Staging of nonsmall-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med. 2003; 348: 2500–2507.

33. Yi C.A., Lee K.S., Kim B.T. et al. Efficacy of helical dynamic CT versus integrated PET/CT for detection of mediastinal nodal metastasis in non-small-cell lung cancer. Am. J. Roentgenol. 2007; 188 (2): 318–325.

34. Rolston K.VI, Rodriguez S., Dhilakia N. et al. Pulmonary infections mimicking cancer: a retrospective, three-year review. Support Care Cancer 1997; 5: 90–95.

35. Schreiber G., McCrory D.C. Performance characteristics of different modalities for diagnosis of suspected lung cancer. Chest 2003; 123 (1, suppl.): 115S–128S.

36. Chin R., McCain T.W., Lucia M.A. et al. Transbronchial needle aspiration in diagnosing and staging lung cancer: how many aspirates are needed? Am. J. Respir. Crit. Care Med. 2002; 166 (3): 377–81.

37. Toloza E.M., Harpole L., Detterbeck F., McCrory D.C. Invasive staging of non-small-cell lung cancer: A review of the current evidence. Chest 2003; 123 (1, suppl.): 157S–166S.

38. Eloubeidi M.A., Tamhane A., Chen V.K., Cerfolio R.J. Endoscopic ultrasound-guided fine-needle aspiration in patients with non-small-cell lung cancer and prior negative mediastinoscopy. Ann. Thorac. Surg. 2005; 80 (4): 1231–1239.

39. Соколов В.В. Современные возможности эндоскопии в онкологии. В кн.: Онкология на рубеже ХХI века, материалы международного научного форума. М.; 1999. 361–363.

40. Lam S. Bronchoscopic, photodynamic, and laser diagnosis and therapy of lung neoplasms. Curr. Opin. Pulm. Med. 1996; 2: 271–276.

41. Okamoto H., Watanabe K., Nagatomo A. et al. Endobronchial ultrasonography for mediastinal and hilar lymph node metastases of lung cancer. Chest 2002; 121: 1498–1506.

42. Wallace M.B., Silvestri G.A., Sahai A.V. et al. Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma of the lung. Ann. Thorac. Surg. 2001; 72: 1861–1867.

43. Shimizu K., Ikeda N., Tsuboi T. et al. Percutaneous CT-guided fine needle aspiration for lung cancer smaller than 2cm and revealed by ground-glass opacity at CT. Cancer 2006; 51 (2): 173–179.

44. Rusch V.W. Mediastinoscopy: An endangered species? J. Clin. Oncol. 2005; 23 (33): 8283–8285.

45. Jiao J., Magistrelli P., Goldstraw P. The value of cervical mediastinoscopy combined with anterior mediastinotomy in the preoperative evaluation of bronchogenic carcinoma of the left upper lobe. Eur. J. Cardiothorac. Surg. 1997; 11: 450–454.

46. Freixinet Gilart J., Garcia P.G., de Castro F.R. et al. Extended cervical mediastinoscopy in the staging of bronchogenic carcinoma. Ann. Thorac. Surg. 2000; 70: 1641–1643.

47. Martin de Nicolas J., Gomez1Caro Andres A., Moradiellos Dies F.J. et al. Importance of routine mediastinal staging in women with non-small-cell lung cancer. Arch. Bronconeumol. 2005; 41 (3): 125–129.

48. Sears D., Hadju S.I. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol. 1987; 31: 87–92.

49. Трахтенберг А.Х., Колбанов К.И., Седых С.А. Рак легкого. В кн.: Чучалин А.Г. (ред.). Респираторная медицина. М.: ГЭОТАР-Медиа; 2007; т. 2: 15–44.

50. Depierre A., Milleron B., Moro1Sibilot D. et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa nonsmall-cell lung cancer. J. Clin. Oncol. 2001; 20: 247–253.

51. Roberts J., Eustis C., Devore R. et al. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small-cell lung cancer. Ann. Thorac. Surg. 2001; 72: 885–888.

52. Scott W.J., Howington J., Movsas B. Treatment of stage II non-small-cell lung cancer. Chest 2003; 123: 188–201.

53. Rice T.W. Blackstone E.H. Radical resections for T4 lung cancer. Surg. Clin. N. Am. 2002; 82 (3): 573–587.

54. Detterbeck F.C., Jones D.R., Kernstine K.H. et al. Lung cancer. Special treatment issues. Chest 2003; 123 (1, suppl.): 244S–258S.

55. Харченко В.П., Чхиквадзе В.Д., Гваришвили А.А. Реконструктивные операции в лечении опухолей легких. В кн.: Материалы 3й Международной конф. по торакальной хирургии. М.; 2005. 126–130.

56. Roviaro G., Vergani C., Maciocco M. et al. Tracheal sleeve pneumonectomy: long-term outcome. Lung Cancer 2006; 52 (1): 105–110.

57. Politi l., Seanagatta P., Salani A. et al. T4 tracheo-bronchial carcinoma: clinical evaluation of sleeve pneumonectomies. Chir Ital. 2004; 56 (6): 787–791.

58. Бисенков Л.Н., Гришаков С.В., Шалаев С.А. Хирургия рака легкого в далеко зашедших стадиях заболевания. СПб.: Гиппократ; 1998.

59. Bernard A., Bouchot O., Hagry O., Favre J.P. Risk analysis and long-term survival in patients undergoing resection of T4 lung cancer. Eur. J. Cardiothorac. Surg. 2001; 20 (2): 344–349.

60. Брюсов П.Г., Васюкевич А.Г., Фокин А.В. Комбинированные операции в тактике лечения немелкоклеточного рака легкого III стадии. В кн.: IX Российский онкологический конгресс, 22–24 нояб.,Москва 2005. М.; 2005. 167.

61. Doddoli C., Rollet G., Thomas P. et al. Is lung cancer surgery justified in patients with direct mediastinal invasion? Eur. J. Cardiothorac. Surg. 2001; 20 (2): 339–343.

62. Guggino G., Doddoli C., Barlesi F. et al. Completion pneumonectomy in cancer patients: experience with 55 cases. Eur. J. Cardiothorac. Surg. 2004; 25 (3): 449–455.

63. Tsuchiya R., Asamura H., Kondo H. et al. Extended recection of the left atrium, great vessels, or both for lung cancer. Ann. Torac. Surg. 1994; 57 (4): 960–965.

64. Matsuoka H., Nichio W., Okada M. et al. Resection of chest wall invasion in patients with non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 2004; 26 (6): 1200–1204.

65. Yokoi K., Tsuchiya R., Mori T. et al. Results of surgical treatment of lung cancer involving diaphragm. J. Thorac. Cardiovasc. Surg. 2000; 120: 799–805.

66. Pearson F.G., DeLarue N.C., Ilves R. et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J. Thorac. Cardiovasc. Surg. 1982; 83 (1): 1–11.

67. Tanaka F., Yanagihara K., Otake Y. Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer. Ann. Surg. Oncol. 2004; 11 (6): 612–618.

68. Ohta Y., Shimixu Y., Minato H. et al. Results of initial operations in non-small-cell lung cancer patients with singlelevel N2 disease. Ann. Thorac. Surg. 2006; 81 (2): 427–433.

69. Suzuki K., Nagai K., Yoshida J. et al. The prognosis of surgically resected N2 non-small-cell lung cancer: the importance of clinical N status. J. Thorac. Cardiovasc. Surg. 1999; 118 (1): 145–153.

70. Усков Д.А., Макеева И.В., Поме А.В. и др. Неоадьювантная химиотерапия немелкоклеточного рака легкого. Рос. онкол. журн. 2001; 3: 4–9.

71. Добродеев А.Ю. Комбинированное лечение рака легкого с интраоперационной лучевой терапией в условиях радиосенсибилизации цисплатином: Автореф. дис. … канд. мед. наук. Томск; 2004.

72. Потанин А.В. Отдаленные результаты хирургического и комбинированного лечения больных немелкоклеточным раком легкого: Автореф. дис. … канд. мед. наук. Казань; 2005.

73. Maas K.W., van Swieten H.A., van Munnink V. et al. Combined modality treatment in stage IIIA/B non-smallcell lung cancer. Lung Cancer 2003; 41 (suppl. 2): 155.

74. De Leyn P., Decker G. Surgical treatment of non-small-cell lung cancer. Rev. Mal. Respir. 2004; 21 (5, pt 1): 971–982.

75. Bradley J.D., Paulus R., Graham M.V. et al. Phase II trial of postoperative adjuvant paclitaxel / carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group-RTOG 9705. J. Clin. Oncol. 2005; 23 (15): 3480–3487.

76. Machtay B.M., Lee J.H., Shrager J.B. et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J. Clin. Oncol. 2001; 19 (19): 3912–3917.

77. Stamatis G., Wilke H., Eberhardt W. et al. Surgery of locally advanced non-small-cell bronchial cancer after intensive preoperative chemo/ radiotherapy. Chirurg 1994; 65 (1): 42–47.

78. Takamori S., Rikimaru T., Hayashi A. et al. A preoperative alternating chemotherapy and radiotherapy program for patients with stage IIIA (N2) non-small-cell lung cancer. Cancer 2000; 29 (1): 49–56.

79. Hainsworth J.D., Gray J.R., Litchy S. et al. A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced nonsmall-cell lung cancer. Clin. Lung Cancer. 2004; 6 (1): 33–42.

80. Friedel G., Hruska D., Budach W. et al. Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer. Lung Cancer 2000; 30 (3): 175–185.

81. Hillejan L., Muller M.R., Eberhardt W., Stuben G. Neoadjuvant chemotherapy and chemoradiotherapy in surgically treated non-small-cell stage III bronchial carcinoma. Kongressbd. Dtsch. Ges. Chir. Kongr. 2001; 118: 601–605.

82. Galetta D., Cesario A., Margaritora S. et al. Enduring challenge in the treatment of non-small-cell lung cancer with clinical stage IIIB: results of a trimodality approach. Ann. Thorac. Surg. 2003; 76: 1802–1809.

83. Бойко А.В., Трахтенберг А.Х. Лучевое и химиолучевое лечение немелкоклеточного рака легкого. В кн.: Трахтенберг А.Х., Чиссов В.И. Клиническая онкопульмонология. М.: ГЭОТАР Медицина; 2000. 394–417.

84. Jeremic B., Milicic B., Acimovic L., Milisavljevic S. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel with erly-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study. J. Clin.Oncol. 2005; 23 (28): 6873–6880.

85. Xia T., Li H., Sun Q. et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2006; 66 (1): 117–125.

86. Marino P., Preatoni A., Cantoni A. Randomized trials of radiotherapy alone vs combined chemotherapy and radiotherapy in stages IIIA and IIIB non-small-cell lung cancer. Cancer 1995; 76: 593–601.

87. Curran W., Scott C., Langer C. et al. Long-term benefit is observed in phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410. Proc. Am. Soc. Clin. Oncol. 2003; 22: 621. abstr. 2499

88. Полоцкий Б.Е., Тер-Ованесов М.Д. Рак легкого – некоторые аспекты клиники, диагностики и лечения. Рус. мед. журн. 2005; 13 (23): 1520–1531.

89. Pirrker R., Krajnik G., Zochbauer S. et al. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 1995; 6 (8): 833–835.

90. von Pawel J., Wagner H., Niederle N. et al. Phase II study of paclitaxel and cisplatin in patients with non-small-cell lung cancer.Semin Oncol. 1996; 23 (6, suppl. 16): 47–50.

91. Noda K., Nishiwaki Y., Kawahara M. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 2002; 346: 85–91.

92. Schild S., Brindle J., Geyer S. et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004; 59: 943–951.

93. Жарков В.В., Моисеев П.И., Курчин В.П. Адьювантная полихимиотерапия и профилактическое облучение головного мозга в лечении оперированных больных мелкоклеточным раком легкого. В кн: Современные технологии в онкологии. Ростов н/Д; 2005; т. 1: 323–324.

94. Зинченко С.В., Потанин В.П. Хирургическое лечение, как профилактика локорегионарных рецидивов при мелкоклеточном раке легкого. В кн: Современные технологии в онкологии. Ростов н/Д.; 2005; т. 1: 324–325.

95. Lewinski T., Zulawski M., Turski C., Pietraszek A. Small-cell lung cancer I-III A: cytoreductive chemotherapy followed by resection with continuation of chemotherapy. Eur. J. Cardiothorac. Surg. 2001; 20 (2): 391–398.

96. Su X.D., Huang Z.F., Rong T.H., Yang M.T. Combined surgical treatment for limited small-cell lung cancer: clinical analysis of 51 cases. Ai Zheng 2003; 22 (10): 1099–1101.

97. Nakamura H., Kato Y., Kato H. Outcome of surgery for small-cell lung cancer – response to induction chemotherapy predicts survival. Thorac. Cardiovasc. Surg. 2004; 52 (4): 206–210.

98. Бычков М.Б. Мелкоклеточный рак легкого. Эволюция химиотерапии за последние 20 лет. В кн.: Материалы III Съезда онкологов и радиологов СНГ. Минск; 2004; ч. 1: 151–153.